Intellia Therapeutics Inc (NASDAQ: NTLA) on Monday, soared 2.23% from the previous trading day, before settling in for the closing price of $14.81. Within the past 52 weeks, NTLA’s price has moved between $13.95 and $34.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 12.09% over the last five years. The company achieved an average annual earnings per share of -0.04%. With a float of $99.79 million, this company’s outstanding shares have now reached $101.58 million.
The firm has a total of 526 workers. Let’s measure their productivity. In terms of profitability, gross margin is 78.53%, operating margin of -1140.05%, and the pretax margin is -1106.87%.
Intellia Therapeutics Inc (NTLA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Intellia Therapeutics Inc is 1.77%, while institutional ownership is 86.09%. The most recent insider transaction that took place on Oct 02 ’24, was worth 38,248. In this transaction VP, Chief Accounting Officer of this company sold 2,012 shares at a rate of $19.01, taking the stock ownership to the 47,012 shares. Before that another transaction happened on Jul 01 ’24, when Company’s EVP, Chief Technical Officer sold 405 for $22.93, making the entire transaction worth $9,287. This insider now owns 71,470 shares in total.
Intellia Therapeutics Inc (NTLA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -0.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.00% during the next five years compared to -22.30% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Intellia Therapeutics Inc (NTLA) is currently performing well based on its current performance indicators. A quick ratio of 7.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 34.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.48, a number that is poised to hit -1.39 in the next quarter and is forecasted to reach -5.58 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Analysing the last 5-days average volume posted by the [Intellia Therapeutics Inc, NTLA], we can find that recorded value of 2.9 million was better than the volume posted last year of 1.64 million. As of the previous 9 days, the stock’s Stochastic %D was 10.71%. Additionally, its Average True Range was 1.12.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 8.36%, which indicates a significant decrease from 15.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 109.56% in the past 14 days, which was higher than the 63.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.72, while its 200-day Moving Average is $23.76. Now, the first resistance to watch is $15.42. This is followed by the second major resistance level at $15.71. The third major resistance level sits at $16.11. If the price goes on to break the first support level at $14.73, it is likely to go to the next support level at $14.33. Now, if the price goes above the second support level, the third support stands at $14.04.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
Market capitalization of the company is 1.60 billion based on 101,579K outstanding shares. Right now, sales total 36,280 K and income totals -481,190 K. The company made 6,960 K in profit during its latest quarter, and -146,980 K in sales during its previous quarter.
